Targeting homologous recombination deficiency in uterine leiomyosarcoma
- Author(s)
- Dall, G; Vandenberg, CJ; Nesic, K; Ratnayake, G; Zhu, W; Vissers, JHA; Bedo, J; Penington, J; Wakefield, MJ; Kee, D; Carmagnac, A; Lim, R; Shield-Artin, K; Milesi, B; Lobley, A; Kyran, EL; O'Grady, E; Tram, J; Zhou, W; Nugawela, D; Stewart, KP; Caldwell, R; Papadopoulos, L; Ng, AP; Dobrovic, A; Fox, SB; McNally, O; Power, JD; Meniawy, T; Tan, TH; Collins, IM; Klein, O; Barnett, S; Olesen, I; Hamilton, A; Hofmann, O; Grimmond, S; Papenfuss, AT; Scott, CL; Barker, HE;
- Details
- Publication Year 2023-05-04,Volume 42,Issue #1,Page 112
- Journal Title
- Journal of Experimental & Clinical Cancer Research
- Publication Type
- Research article
- Abstract
- BACKGROUND: Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations in the homologous recombination (HR) DNA repair pathway have been observed in ~ 10% of uLMS cases, with reports of some individuals benefiting from poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) therapy, which targets this DNA repair defect. In this report, we screened individuals with uLMS, accrued nationally, for mutations in the HR repair pathway and explored new approaches to therapeutic targeting. METHODS: A cohort of 58 individuals with uLMS were screened for HR Deficiency (HRD) using whole genome sequencing (WGS), whole exome sequencing (WES) or NGS panel testing. Individuals identified to have HRD uLMS were offered PARPi therapy and clinical outcome details collected. Patient-derived xenografts (PDX) were generated for therapeutic targeting. RESULTS: All 13 uLMS samples analysed by WGS had a dominant COSMIC mutational signature 3; 11 of these had high genome-wide loss of heterozygosity (LOH) (> 0.2) but only two samples had a CHORD score > 50%, one of which had a homozygous pathogenic alteration in an HR gene (deletion in BRCA2). A further three samples harboured homozygous HRD alterations (all deletions in BRCA2), detected by WES or panel sequencing, with 5/58 (9%) individuals having HRD uLMS. All five individuals gained access to PARPi therapy. Two of three individuals with mature clinical follow up achieved a complete response or durable partial response (PR) with the subsequent addition of platinum to PARPi upon minor progression during initial PR on PARPi. Corresponding PDX responses were most rapid, complete and sustained with the PARP1-specific PARPi, AZD5305, compared with either olaparib alone or olaparib plus cisplatin, even in a paired sample of a BRCA2-deleted PDX, derived following PARPi therapy in the patient, which had developed PARPi-resistance mutations in PRKDC, encoding DNA-PKcs. CONCLUSIONS: Our work demonstrates the value of identifying HRD for therapeutic targeting by PARPi and platinum in individuals with the aggressive rare malignancy, uLMS and suggests that individuals with HRD uLMS should be included in trials of PARP1-specific PARPi.
- Publisher
- BioMed Central
- Keywords
- Female; Humans; *Leiomyosarcoma/drug therapy/genetics/pathology; Platinum; Piperazines/pharmacology/therapeutic use; *Uterine Neoplasms/drug therapy/genetics; Poly(ADP-ribose) Polymerases; Recombinational DNA Repair; *Ovarian Neoplasms/pathology; Homologous Recombination; Homologous recombination deficiency; PARP inhibitors; Patient-derived xenografts; Rare cancers; Uterine leiomyosarcoma
- Department(s)
- Medical Oncology; Laboratory Research; Cancer Imaging; Health Services Research
- PubMed ID
- 37143137
- Publisher's Version
- https://doi.org/10.1186/s13046-023-02687-0
- Open Access at Publisher's Site
https://doi.org/10.1186/s13046-023-02687-0- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-08-15 07:31:22
Last Modified: 2023-08-15 07:32:14